Application Value of Urine NMP22, OPN, and BTA Detection in the Diagnostic and Prognostic Evaluation of Bladder Urothelial Carcinoma

Objective: To investigate the application value of urine nuclear matrix protein 22 (NMP22), osteopontin (OPN), and bladder tumor antigen (BTA) detection in the diagnostic and prognostic evaluation of bladder urothelial carcinoma. Methods: 100 patients with bladder urothelial carcinoma who visited our hospital from January 2020 to December 2022 were selected as the case group, and 100 healthy individuals who underwent physical examination during the same period were selected as the control group. The levels of NMP22, OPN, and BTA in the urine of the two groups were detected, and their diagnostic efficacy in bladder urothelial carcinoma was analyzed. The patients in the case group were followed up to observe the relationship between these markers and prognosis. Results: The levels of NMP22, OPN, and BTA in the urine of the case group were significantly higher than those of the control group (P < 0.05). The sensitivity, specificity, and accuracy of combined detection of NMP22, OPN, and BTA for diagnosing bladder urothelial carcinoma were higher than those of single marker detection (P < 0.05). Follow-up results showed that patients with high levels of NMP22, OPN, and BTA had a higher recurrence rate and shorter progression-free survival (P < 0.05). Conclusion: Combined detection of urine NMP22, OPN, and BTA has high diagnostic value for bladder urothelial carcinoma, and the levels of these markers are correlated with patient prognosis, which can be used for prognostic evaluation.